Press releases

Eevia Health publishes Information Memorandum regarding the Rights Issue

NOT FOR PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, OR ANY OTHER COUNTRY IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE REQUIRES FURTHER ACTION IN ACCORDANCE WITH THE PREVIOUS STATEMENT OR IS CONTRARY TO THE RULES IN SUCH COUNTRY. DISPUTES ARISING FROM THE CONTENTS OF THE MEMORANDUM OR RELATED LEGAL RELATIONSHIPS SHALL BE SETTLED IN ACCORDANCE WITH SWEDISH LAW AND IN SWEDISH COURTS.             

Eevia Health Plc ("Eevia" or "The Company") publishes today an information memorandum by reason of the Rights Issue of shares based on an authorization from the Extraordinary General Meeting held on October 11, 2022, in accordance with the shareholders' pre-emptive subscription right, to issue up new shares with preferential rights in the Company for existing shareholders and the general public in Sweden ("Offer").

The Offer, if fully subscribed, is expected to provide Eevia with SEK 21,6 million before the deduction of expenses related to the Offer. The expected costs are approximately SEK 3 million. The Rights Issue is secured through subscription commitments corresponding to approximately 43 percent of the Offer volume, and underwriting commitments of approximately 39 percent of the Offer volume, resulting in 82 percent in total.

Information memorandum and application form

The information memorandum for the issue is now published on Eevia's website, https://eeviahealth.com, and on Partner Fondkommission AB's website at www.partnerfk.com. An application for the subscription without subscription rights is to be made on the form "Subscription without subscription rights" available for downloading from Partner Fondkommission's website (www.partnerfk.se),  at the website of the Company (www.eeviahealth.com), and at Spotlight Stock Market's website (www.spotlightstockmarket.com).

 

Briefly about the Rights Issue:

  • All shareholders registered in Eevia's shareholder register maintained by Euroclear Finland or Euroclear Sweden on the record date of October 27, 2022, will be allocated one (1) subscription right for each share held
  • Ten (10) such subscription rights entitle subscription of nine (9) new shares
  • Subscription of shares will commence on November 1, 2022, at 09:30 Finnish time (08:30 Swedish time) and is expected to end on November 15, 2022, at 16:30 Finnish time (15:30 Swedish time) in Sweden and on November 17, 2022 at 16:30 Finnish time (15:30 Swedish time) in Finland
  • The subscription price is SEK 1,50 (EUR 0,133) per share
  • The Company will approximately receive SEK 21,6 million upon full subscription of the Rights Issue
  • Trading in subscription rights is ongoing from and including November 1, 2022 until and including November 10, 2022
  • Trading in BTA (paid subscription shares) is ongoing from and including November 1, 2022, until the Rights Issue has been registered with the Finnish Trade Register

The Company received, on October 20, 2022, legally binding pre-subscription commitments of approximately SEK 9,3 million, which corresponds to approximately 43 percent of the Offer volume, and underwriting commitments of approximately SEK 8,3 million, which corresponds to approximately 39 percent of the Offer volume, resulting in 82 percent in total.

Advisors

In association with the Offer as described in this Memorandum, Partner Fondkommission is the financial adviser and issuer agency to Eevia in Sweden, and OP Bank is issuer agent in Finland.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                             Joel Westerström, Partner Fondkommission

Email: stein.ulve@eeviahealth.com                        Email: joel.westerstrom@partnerfk.se

Telephone: +358 400 22 5967                                 Telephone:   +46 735 11 68 53

IMPORTANT INFORMATION ABOUT THE PRESS RELEASE AND DOCUMENTS

This press release does not constitute an offer to acquire, subscribe to, or otherwise trade in shares, subscription rights, paid subscription shares, or other securities in Eevia Health Plc. Investors must subscribe to or acquire securities only based on the information in the IM, which will be published before the start of the subscription period for the Rights Issue. No action has been taken and no action will be taken to permit an offer to the public in any jurisdiction other than Sweden.

This press release must not be published or distributed, directly or indirectly, to or within Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the US, or any other jurisdiction where the distribution of this press release is against the law. Similarly, this press release does not constitute an offer to sell new shares, paid subscription shares, subscription rights, or other securities to anyone in a jurisdiction where it is not allowed to make such an offer to such a person, or where such action would require an additional prospectus, registration, or measures other than those required under Swedish law.

The IM, registration slip, and other documents attributable to the Rights Issue may not be distributed to or within any country where such distribution or Rights Issue requires measures as stated in the preceding sentence, or where this would contravene the law of that country.

No shares, subscription rights, paid subscription shares, or other securities have been registered or will be registered pursuant to the 1933 United States Securities Act in its current version ("the Securities Act") or securities legislation in any state or other jurisdiction of the US, and may not be offered, subscribed to, utilized, pledged, sold, resold, granted, supplied, or otherwise transferred, directly or indirectly, to or within the US, except in accordance with any applicable exemption from or by a transaction that is not covered by the registration requirements of the Securities Act and in accordance with the securities legislation in the relevant state or other jurisdiction of the US.

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas. 

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

2023-01-18
Regulatory

Eevia Health ("Eevia" or "The Company") received a sales order from a US customer for the elderberry extract Feno-Sambucus™ 7 Organic for a value of just over USD 200k or EUR 187k.

2023-01-16
Regulatory

Stein Ulve, the Chief Executive Officer (CEO) of Eevia Health Plc, ("Eevia" or "The Company") has sold 112 782 shares in The Company to Harri Salo, the Chief Manufacturing Officer (CMO) of Eevia.

2023-01-13

Due to a misjudgement, the MAR label was added to the original press release. The press release did not contain any insider information or other reason for the MAR label. This press release is a correction without the MAR label. 

Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.

2023-01-13
Regulatory

Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.

2022-12-19
Regulatory

Eevia Health Plc's ("Eevia" or "the Company") preferential rights issue has now been registered with the Finnish Trade Register. Paid Subscription Shares (Swedish: BTA) will thus be replaced by ordinary shares. The last day for trading with BTA on Spotlight Stock Market is 22 December 2022, and new shares are expected to be booked into the respective custodian/VP account on 29 December 2022.

2022-12-05
Regulatory

Stein Ulve, the CEO of Eevia Health Plc, ("Eevia" or "The Company"), subscribed for 489 996 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed. Stein Ulve had 1 907 500 subscription rights, but he subscribed for 489 996 shares. Consequently, he was diluted under the flagging threshold of 10%.

2022-12-05
Regulatory

Eevia Health Plc ("the Company" or "Eevia") has become aware that Marizoe Actives S.L. from Madrid, Spain has subscribed for 1 517 459 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed, leading to a new total of shares of 30 349 371. Marizoe Actives S.L. had no shares before the issue and with the subscription, Marizoe has 5.01% of the new outstanding shares.

2022-12-01
Regulatory

Eevia Health ("Eevia" or "The Company") received a start order for the Feno-Sambucus™ worth SEK 110 000 from its Australian distributor Ingredient Plus. The order is a new start order for an Australian brand owner.

2022-11-30
Regulatory

Eevia Health Plc's ("Eevia" or "The Company") has received a 41 KEUR sales order for Bilberry extract from its distributor in France Natural Ingredients.

2022-11-30

Eevia Health has commissioned a new High-Performance Liquid Chromatography (HPLC) analytical equipment from Shimadzu, which significantly increases the capacity to undertake analyses of polyphenols.

1
2
...
8
>>